At April’s SupplySide East trade show, Sabinsa Corp. (East Windsor, NJ) explained how its branded Coleus forskohlii extract ingredient, ForsLean, is approaching the weight management and metabolic health market in a new way. Recently, the company announced it received new patents in several countries based on newly gleaned information about how the ingredient, which was primarily marketed as a body-composition ingredient, works to achieve what Sabinsa is now calling “energy balance”—that is, the conversion of white fat to brown fat. (The patents are: Japan Patent Number 6472453, U.S. Patent Number 10085963, and Australian Patent Number 2015351423.)
In a press release, the company described the effects of ForsLean and its active constituent, forskolin, thusly: “Whereas Sabinsa’s original ForsLean patents defined its use and composition in promotion of lean body mass, reduction of adipose tissue (fat), and weight loss, the new patents outline a molecular mechanism: how forskolin actually aids in fat conversion into heat, a novel concept called energy balance. Humans possess white fat tissue (WAT) and brown fat tissue (BAT). While WAT stores energy in the form of triglycerides, BAT dissipate energy in the form of heat. Forskolin, by recruiting secretory factors like bone morphogenic factors (BMPs), aids in the conversion of WAT to BAT, which is crucial for fat utilization and effective energy utilization (balance). This is a preferred preventive measure from obesity and metabolic imbalance.”
Read More